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Abstract Regulatory T cells (Tregs) have been implicated
as inhibitors of antitumor immune reactions. However, data
on the relevance of their prevalence at tumor sites in
influencing disease outcome are controversial. The aim of
our study was to investigate the role in tumor progression
and the prognostic impact of the density of lymphocytes
expressing FOXP3, a transcription factor expressed pre-
dominantly by CD4+CD25+ Tregs, in primary cutaneous
melanoma. We examined the infiltration of FOXP3+ cells
by immunohistochemistry in tumor samples from 97
patients and evaluated in relation to patient and tumor
parameters. The degree of infiltration by FOXP3+ cells did
not show correlation with the thickness of melanomas.
Moreover, no associations were found with metastasis
formation during the 5-year follow-up period, patient
survival, or any other clinicopathologic parameters studied.
These results suggest that the presence of FOXP3+
lymphocytes in primary tumors is not of prognostic
importance in human cutaneous melanoma.
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Introduction
Human solid tumors are often infiltrated by CD4+ and
CD8+ lymphocytes, and numerous tumor-associated anti-
gens have been discovered that can stimulate these cells
after presentation by antigen-presenting cells in the context
of the appropriate MHC molecules, inducing tumor-specific
cytokine production or tumor cell lysis [1]. However, tumor
progression is frequently seen in the presence of substantial
lymphocytic infiltration, suggesting that this immune
response is apparently incapable of controlling tumor
growth. Escape mechanisms that might explain the lack of
effectiveness of antitumor immune reactions include down-
regulation of tumor-associated antigens (TAA) or MHC
class I molecules, insufficient presentation of antigenic
peptides, lack of costimulation, or inhibition of tumor-
reactive T cells by immune suppressive factors or cells
(reviewed in ref. [2]).
Numerous suppressor cell types have been identified that
could contribute to the decrease in antitumor immune
functions, including, among others, regulatory T cells,
myeloid-derived suppressor cells and plasmacytoid
dendritic cells [3]. The best characterized cell type is
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CD4+CD25+FOXP3+ regulatory T (Treg) cells, which
comprise a functionally unique population of T lymphocytes
controlling proliferation and function of other CD4+ as well
as of CD8+ T cells, thus mediating peripheral tolerance.
Natural Tregs arise in the thymus, but adaptive Tregs may
also develop by conversion of CD4+CD25−FOXP3− cells at
the periphery. Regulatory T cells are crucial in preventing
autoimmune responses, and are implicated in a broad
spectrum of autoimmune diseases, as well as in allograft
rejection, graft-versus-host disease and allergy.
The role of Treg cells in cancer has recently been the focus
of intense investigation. These cells have been found in
increased number in the peripheral blood of cancer patients
compared to healthy controls, and their accumulation in the
tumor tissue has been demonstrated in the case of many
cancer types (reviewed in ref. [4]).
Although a high number of functional regulatory T cells
in the tumor microenvironment may be indicative of a local
suppression of T cell immunity, the pathophysiological
importance of Treg accumulation in human malignancies
has remained questionable. Reports on the prognostic role
of tumor-infiltrating Tregs are inconclusive; while in some
cancer types their increased level has been correlated with
poor outcome, as in the case of ovarian, breast, pancreatic
and hepatocellular carcinomas [5–9], in others including
prostate and renal cancers no significant associations were
found [10, 11], and in the case of head and neck
carcinomas, colorectal cancer, as well as in several
lymphoma types a marked infiltration by Tregs showed
correlation with improved survival [12–17].
Few studies have addressed the presence of regulatory T
lymphocytes and its potential clinical correlates in melano-
ma, most of them comprising data on a limited number of
patients and yielding controversial results. Mourmouras et
al characterized cutaneous melanocytic lesions including
melanomas with respect to the prevalence of Tregs, and
found a lower percentage of Tregs in vertical than in radial
growth phase melanomas [18]. Contrary to this finding,
another small-scale study described higher prevalence of
these cells in VGP compared to RGP, and also in stage III–
IV tumors compared to stage I ones [19]. Miracco et al, in a
study performed on vertical growth phase melanomas,
reported that high intra- and peritumoral percentage of
Tregs predicted local recurrence [20]. On the other hand, no
correlation of the number of FOXP3+ lymphocytes with
Breslow index or patient survival was found by Hillen et al
[21]. Thus far, no systematic studies were performed
correlating the extent of Treg infiltration of primary
cutaneous melanoma with several clinicopathologic factors
in large patient cohorts, providing conclusive data on the
clinical relevance of these cells.
In a previous study examining the prevalence of
activated T cells in cutaneous melanomas, we found a
decreased peritumoral infiltration by T lymphocytes
expressing CD25 or OX40 in tumors developing distant
metastases during a follow-up period of 5 years, compared
to nonmetastatic or lymph node metastatic ones. Accord-
ingly, high peritumoral densities of CD25+ or OX40+
lymphocytes were associated with longer survival of the
patients [22]. Furthermore, we also identified the density of
DC-LAMP+ mature DCs, as well as combinations of high
peritumoral CD1a+ or DC-LAMP+ cell densities with high
numbers of CD25+ or OX40+ lymphocytes as prognostic
factors in melanoma patients [23]. This suggests that the
presence of activated T cells and antigen presenting DCs at
the primary site could be a marker of a functional immune
response against melanoma progression and influence the
outcome of the disease. In the present study we examined
the role of regulatory T cells, another subset of T
lymphocytes with a presumed opposing function, in these
processes. We investigated the prevalence of lymphocytes
expressing the FOXP3 marker by immunohistochemistry in
primary tumor samples from 97 patients with cutaneous
melanoma, and evaluated with regard to its association with
tumor thickness, the development of metastases, patients’
survival, and other clinicopathologic parameters.
Materials and Methods
Tumor Samples
Archival tissue samples were obtained from 97 patients
with primary cutaneous melanoma who underwent surgery
between 1980 and 2001 at the Institute of Dermato-
Venerology, Semmelweis University, and at the National
Institute of Oncology, Budapest. Patients were selected in
order to obtain a study group involving a higher number of
intermediate-thickness or thick (>1.0 mm) melanoma
samples than their normal ratio, which have a more
uncertain prognosis than thin tumors. The study was
approved by the ethics committees of both institutions.
Patients did not receive any anticancer treatment prior to
surgery. Clinical and pathological characteristics are sum-
marized in Table 1. The tumors were grouped into four
thickness categories based on the AJCC staging system [24]
(≤1.0, 1.01–2.0, 2.01–4.0, >4.0 mm), and into three
categories according to disease progression (nonmetastatic,
lymph node metastatic, visceral metastatic). Distribution
according to stages [24] was: st. IA, 10; IB, 11; IIA, 17;
IIB, 28; IIC, 14; IIIA, 14; IIIB, 3. Surviving patients had
follow-up data for at least 5 years; none of the patients died
of melanoma-unrelated causes within 5 years. Forty-five
patients had no metastases developed during the follow-up
period, while eight had metastases confined to regional
lymph nodes, which were excised. Fourty-four patients
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developed distant visceral metastases. Five-year survival of
patients in both the nonmetastatic and the lymph node
metastatic groups was 100%, while only two patients
developing distant visceral metastases survived for more
than 5 years (62 and 72 months). Tumors with clinical
regression and/or histological signs of extensive regression
were not included in the study.
Immunohistochemical Detection of Infiltrating Cells
Three-μm sections cut from formalin-fixed, paraffin-
embedded cutaneous melanoma samples were used. Immu-
nohistochemistry was performed as described earlier [22],
using monoclonal anti-FOXP3 (236A/E7; Abcam Inc.,
Cambridge, MA) primary antibody, followed by biotin/
streptavidin-peroxidase method (LSAB2 System, HRP;
Dako, Glostrup, Denmark) and visualization with 3-amino-
9-ethylcarbazole (Vector Laboratories, Inc., Burlingame,
CA).
Evaluation of the Immune Reactions
Slides were examined using a graticule of 10×10 squares,
calibrated as 0.25 mm2 at 200× magnification. Because the
distribution of stained cells was heterogeneous, the entire
tumor area was analyzed in every case, and density of
positive cells/mm2 is given. Although a few larger cells
with morphological features of melanoma cells also showed
nuclear FOXP3 staining in some instances, the majority of
labeled cells had lymphocytic morphology, and only these
cells were counted. The number of FOXP3+ lymphocytes
was registered separately in intratumoral (infiltrating mel-
anoma cell nests) and peritumoral areas (distributed in the
infiltrate along the margin and the base of melanomas). In 3
areas of the highest density of positive cells the ratio of
FOXP3+ lymphocytes was also determined as a percentage
of the total cell number in the given field, using high
magnification (400×). The proportion of patients with
significant density of FOXP3+ cells was calculated using
cutoff values set up separately for intra- and peritumoral
localization as well as for the ratio of positive cells (30 and
220 cells/mm2, and 11%, respectively), based on the
median of the given variable in the whole patient group.
Statistical Analysis
Comparisons between cell densities in different tumor
groups was made using the Mann-Whitney U test and
Kruskal-Wallis test, while χ2 test was used for comparing
the proportions of samples with high cell densities.
Association between tumor thickness and cell density
values was evaluated by the Pearson test. Univariate
Patient group All patients Nonmetastatic LN metastatica Visceral metastatic
Age–median (range) 54 (27–76) 50 (27–76) 58 (45–76) 56 (32–76)
Sex
Male 43 16 4 23
Female 54 29 4 21
Tumor thickness (mm)
≤1.0 11 10 1 –
1.01–2.0 21 12 3 6
2.01–4.0 37 14 3 20
>4.0 28 9 1 18
Tumor site
Extremities 41 21 4 16
Trunk 53 23 4 26
Head 3 1 – 2
Histologic type
SSM 58 30 5 23
NM 33 13 2 18
ALM 4 1 1 2
LMM 1 – – 1
desm. 1 1 – –
Ulceration
Present 48 15 4 29
Absent 49 30 4 15
5-year survival (%) 55/97 (57) 45/45 (100) 8/8 (100) 2/44 (5)
Table 1 Patient and tumor
characteristics
SSM superficial spreading
melanoma, NM nodular
melanoma, ALM acral lentigi-
nous melanoma, LMM lentigo
maligna melanoma, desm.
desmoplastic
a only regional lymph node
metastases during the follow-up
period (5 years)
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analysis of survival was performed by the Kaplan-Meier
method, and the statistical analysis was carried out by the
Mantel-Cox test. All statistics were calculated using the
BMDP Statistical Software Pack.
Results
Detection of FOXP3+ Lymphocytes in Melanoma Samples
In the melanoma samples, nuclear staining for FOXP3 was
detected predominantly in small lymphocytes (Fig. 1).
Occasionally, larger cells with morphological features of
melanoma cells with nuclear FOXP3 staining were noted.
Few positive cells were found in the uninvolved skin or
dermal areas.
The density of FOXP3+ lymphocytes was determined
separately in intratumoral (inside melanoma cell nests) and
peritumoral areas (surrounding the tumor deposits). Lym-
phocytes stained for FOXP3 were more abundant in the
tumor stroma, with a six-fold difference in average
compared to their intralesional density (mean±SD, 292.2±
211.5 vs. 48.8±63.2 cells/mm2). In three areas of the
highest density of positive cells the ratio of FOXP3+
lymphocytes was also calculated as a percentage of the
total cell number in the given field, and was estimated as
11.9±5.8% for the whole patient group.
Correlations Between FOXP3+ Cell Density
and Clinicopathologic Parameters
The degree of either intra- or peritumoral infiltration by
FOXP3+ lymphocytes, or the ratio of positive cells did not
show significant correlation with Breslow index (r=
−0.1285, r=−0.1193 and r=−0.0048, respectively; p>
0.05). Although intermediate thickness tumors (between 1
and 4 mm) displayed increased intratumoral density (p=
0.0039 by Kruskal-Wallis test), no such differences were
found in the case of either peritumoral density or the ratio
of positivity (Fig. 2a). Moreover, no difference was found
in FOXP3+ cell number between primary tumors accord-
ing to their metastasis formation during a follow-up period
of 5 years (p=0.8292, p=0.2337 and p=0.1803 for intra-,
peritumoral density and positivity ratio, respectively;
Fig. 2b).
For intra- and peritumoral densities, as well as for the
ratio of FOXP3+ cells, we calculated the proportions of
samples with values higher than the median of the given
variable in the whole patient group (30 and 220 cells/mm2,
and 11%, respectively). Analyzing the relationship between
the ratio of samples with high FOXP3+ cell numbers and
tumor thickness or the metastatic pattern of the tumor, no
significant differences were observed, with the exception of
a higher frequency of samples with elevated intratumoral
density of labeled cells in the groups of intermediate
thickness tumors (Table 2). The distribution of melanomas
with high FOXP3+ cell densities was also analyzed
according to other clinicopathologic factors as patient age
and gender, tumor location and the presence or absence of
ulceration, with no associations found in the case of any of
these parameters (Table 2). Concerning histological type,
SSM and NM cases were compared only in the >2.0 mm
thickness categories, since only 2 nodular melanomas were
included in the thinner tumor groups; in these cases no
difference in FOXP3+ cell content was found.
Survival Analysis According to FOXP3+ Cell Density
To evaluate the prognostic impact of the infiltration by
FOXP3+ lymphocytes, we performed Kaplan-Meier analysis
using the medians as cutoff levels as described above.
Neither intra- or peritumoral densities, nor the ratio of
positive cells showed any significant association with the
survival of the patients (p=0.4890, p=0.6245 and p=0.2711,
respectively). The percentage of patients with more than 5
years survival was similar irrespective of the amount of
FOXP3+ cells (60% vs. 53%, p=0.5327, 59% vs. 54%, p=
0.6181 and 51% vs. 62%, p=0.2773, for high or low intra-
and peritumoral cell densities, and high or low positive cell
ratios, respectively).
Discussion
In the present report, we determined the density of FOXP3+
lymphocytes in primary tumors of patients with malignant
melanoma, and analyzed in relation to clinicopathologic
parameters.
Fig. 1 FOXP3+ cells in primary melanoma sample. Picture was taken
using ×20 objective
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FOXP3+ cells were more prevalent in the stromal,
lymphocyte-rich areas than in tumor cell nests, similarly
to observations on other tumor types [6, 12]. Occasional
positive staining of larger cells with morphological features
of melanoma cells could also be found, in accordance with
observations by Ebert et al [25]. Nevertheless, the over-
whelming majority of FOXP3 staining was detected in
small lymphocytes. We did not make attempts to charac-
terize the labeled cell type(s) more precisely by double
immunohistochemical staining. Although the expression of
FOXP3 could be induced in vitro in CD4+CD25− and CD8+
lymphocytes as well [26–29], in previous immunohisto-
chemical studies on melanoma all FOXP3+ cells expressed
CD3 and almost all of them CD4 and CD25 as well [18,
19], suggesting that the vast majority of tumor-infiltrating
FOXP3+ cells are CD4+CD25+ T lymphocytes.
The use of archival samples in our study did not allow the
examination of the functional characteristics of the labeled
cells. Since CD25 is expressed on activated T lymphocytes
beside Tregs, FOXP3 has been considered the most reliable
marker for immunohistochemical determination of the latter
cells. It is a transcription factor critical for the development
and function of regulatory T cells [30–33], and its expression
is generally considered to define Tregs with suppressive
capability [31–34]. On the other hand, in recent studies it
became clear that the role of human FOXP3 is different from
that of its murine counterpart, being a consequence of
activation status, and responsible for an anergic phenotype,
but not necessarily for a regulatory function of cells that
express it [4, 26, 28, 34–36]. Nevertheless, a suppressive
capacity of CD4+CD25highFOXP3+ cells isolated from
human tumors was demonstrated by Kryczek et al. [37].
In any case, FOXP3-positive lymphocytes infiltrating
primary human melanomas do not appear to exert a
suppressor activity that would be reflected in the later
course of the disease. Although their presence seemed to
make a difference in terms of local recurrence of VGP
melanomas [20], it did not influence either the development
of metastases or survival of melanoma patients according to
our study. With regard to the lack of effect on survival, our
results corroborate those of an earlier report [21]. To the
best of our knowledge, however, ours is the first study that
Fig. 2 Intra- and peritumoral
density, and the highest ratio
of FOXP3+ cells (mean±SE),
according to melanoma
thickness (a) and metastasis
formation (b)
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systematically analyzed the associations of Treg infiltration
with several clinicopathologic factors in a large patient
cohort, in an attempt to provide conclusive data on the
clinical relevance of these cells in melanoma. Since the
amount of FOXP3+ cells did not show association with any
of the studied parameters: patient age or gender, tumor
thickness, location, histological type, ulceration and, most
importantly, the outcome of the disease, as mentioned
above, FOXP3+ cell infiltration in the primary tumor does
not seem to have a significant impact on the course of the
disease in cutaneous melanoma. Previous studies aiming at
the clinical relevance of tumor-infiltrating Tregs have given
rise to contradictory results, showing correlation with poor
outcome in some cancer types [5–9] but no association or
even correlation with improved survival in others [10–17,
21]. It could be suggested that each tumor type behaves
differently in this context [4], depending perhaps on other
players on the scene of antitumor immune reactions and
their complex functional interrelationships with Tregs as
well as with tumor cells.
In conclusion, we have shown that the density of
FOXP3+ lymphocytes in the primary tumor is not signif-
icantly associated with clinicopathologic parameters and
has no prognostic value in patients with cutaneous
melanoma.
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Table 2 Proportion of patients with high FOXP3+ cell density according to patient and tumor characteristics
Patient no. Intratumorala Peritumoral Highest ratio of positivity
(≥30 cells/mm2) (≥220 cells/mm2) (≥11%)
No. (%) p No. (%) p No. (%) p
All patients 97 47 (50) 49 (51) 47 (48)
Age
≤54 years 50 28 (57) 26 (52) 24 (48)
>54 years 47 19 (42) n.s. 23 (49) n.s. 23 (49) n.s.
Sex
Male 43 21 (50) 22 (51) 19 (44)
Female 54 26 (50) n.s. 27 (50) n.s. 28 (52) n.s.
Tumor thickness (mm)
≤1.0 11 4 (36) 5 (45) 6 (55)
1.01–2.0 21 14 (70) 13 (62) 13 (62)
2.01–4.0 37 22 (61) 20 (54) 17 (46)
>4.0 28 7 (26) 0.0072 11 (39) n.s. 11 (39) n.s.
Tumor site
Extremities 41 18 (46) 18 (44) 19 (46)
Axial (trunk + head) 56 29 (53) n.s. 31 (55) n.s. 28 (50) n.s.
Histologic typeb
SSM 31 17 (55) 16 (52) 14 (45)
NM 31 11 (38) n.s. 14 (45) n.s. 13 (42) n.s.
Ulceration
Present 48 26 (55) 27 (56) 24 (50)
Absent 49 21 (45) n.s. 22 (45) n.s. 23 (47) n.s.
Metastatic pattern
Nonmetastatic 45 22 (51) 23 (51) 20 (44)
LN metastatic 8 5 (62) 6 (75) 4 (50)
Visceral metastatic 44 20 (47) n.s. 20 (45) n.s. 23 (52) n.s.
n.s. not significant, SSM superficial spreading melanoma, NM nodular melanoma, ALM acral lentiginous melanoma, LMM lentigo maligna
melanoma
a Three cases could not be evaluated
b ALM (4), LMM (1) and desmoplastic (1) cases are not shown; only for cases >2.0 mm
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